Dr. Klein has a noteworthy stake in PTC Therapeutics, reflecting his commitment to the company. Following his promotion to CEO in March 2023, he received significant equity awards that include 130,000 stock options and 127,000 restricted stock units. His holdings...
Dr. Klein has a noteworthy stake in PTC Therapeutics, reflecting his commitment to the company. Following his promotion to CEO in March 2023, he received significant equity awards that include 130,000 stock options and 127,000 restricted stock units. His holdings peaked when he transitioned to this CEO role and continued to grow due to various grants linked to performance milestones. His insider ownership level indicates his strong belief in PTC's future, as he has previously held positions where he made strategic decisions that positively affected company performance and stock value. As of the latest reports, he holds shares that demonstrate both his confidence in PTC's direction and his long-term investment in the company’s success.